Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice
Lei Sun,Xiaoxiao Yang,Qi Li,Peng Zeng,Ying Liu,Lipei Liu,Yuanli Chen,Miao Yu,Chuanrui Ma,Xiaoju Li,Yan Li,Rongxin Zhang,Yan Zhu,Qing Robert Miao,Jihong Han,Yajun Duan
DOI: https://doi.org/10.1161/ATVBAHA.117.309630
2017-01-01
Arteriosclerosis Thrombosis and Vascular Biology
Abstract:Objective-The reduced adiponectin levels are associated with atherosclerosis. Adiponectin exerts its functions by activating adiponectin receptor (AdipoR). Proprotein convertase subtilisin kexin type 9 (PCSK9) degrades LDLR protein (low-density lipoprotein receptor) to increase serum LDL-cholesterol levels. PCSK9 expression can be regulated by PPAR gamma (peroxisome proliferator-activated receptor.) or SREBP2 (sterol regulatory element-binding protein 2). The effects of AdipoR agonists on PCSK9 and LDLR expression, serum lipid profiles, and atherosclerosis remain unknown. Approach and Results-At cellular levels, AdipoR agonists (ADP355 and AdipoRon) induced PCSK9 transcription/expression that solely depended on activation of PPAR-responsive element in the PCSK9 promoter. AdipoR agonists induced PPAR gamma expression; thus, the AdipoR agonist-activated PCSK9 expression/production was impaired in PPAR gamma deficient hepatocytes. Meanwhile, AdipoR agonists transcriptionally activated LDLR expression by activating SRE in the LDLR promoter. Moreover, AMP-activated protein kinase alpha (AMPK alpha) was involved in AdipoR agonist-activated PCSK9 expression. In wild-type mice, ADP355 increased PCSK9 and LDLR expression and serum PCSK9 levels, which was associated with activation of PPAR gamma, AMPK alpha and SREBP2 and reduction of LDL-cholesterol levels. In contrast, ADP355 reduced PCSK9 expression/secretion in apoE-deficient (apoE(-/-)) mice, but it still activated hepatic LDLR, PPAR gamma, AMPK alpha, and SREBP2. More importantly, ADP355 inhibited lesions in en face aortas and sinus lesions in aortic root in apoE(-/-) mice with amelioration of lipid profiles. Conclusions-Our study demonstrates that AdipoR activation by agonists regulated PCSK9 expression differently in wildtype and apoE(-/-) mice. However, ADP355 activated hepatic LDLR expression and ameliorated lipid metabolism in both types of mice and inhibited atherosclerosis in apoE(-/-) mice. Visual Overview-An online visual overview is available for this article.